Key to new Cancer drugs discovered in bacterial genomes
Achievement is made by the scientists of The Scripps Research Institute (TSRI) Florida campus who had previously discovered LNM E1 compound used to kill prostate cancer. This time they have unlocked the capability of LNM family molecules by “mining” the information stored in bacterial genomes and bringing them even closer to the clinical trials. Present research results suggest that these hidden genes hold the key to developing new, even more, effective cancer-targeting compounds.
New Research paper could increase pressure on CRISPR biotechs
Recently published paper in a journal has revealed that a “cutting” element of the CRISPR-Cas9 gene-editing technique could be considered as a potential threat to body’s own immune system.
Paper published on bioRxiv (yet to be reviewed), saw researchers result on blood tests taken from a few dozen people. Results have shown the presence of pre-existing adaptive immune responses in humans to either Cas9 homolog that may hinder the efficacious and safe use of the Cas9/gRNA system to treat disease and might result in significant toxicity to host.
Clinical trials to be initiated for BioAtla’s Conditionally Active Biologics in CAR-T Candidates for Solid Tumors in China
Global biotechnology company BioAtla, LLC, focused on the development of Conditionally Active Biologic (CAB) protein therapeutics has recently announced that Shanghai Sinobioway Sunterra Biotechnology has received ethics committee approval of a clinical trial for two novel, conditionally active chimeric antigen receptor T cell (CAB-CAR-T) products. The drug candidates are designed to target Axl and Ror2 for the treatment of metastatic renal cell carcinoma.
Ascentage Pharma has recently got acceptance of IND application by China FDA for Clinical Study of Novel IAP Inhibitor for treating Hepatitis B infection
The global clinical-stage biopharmaceutical company, Ascentage Pharma dedicated to developing apoptosis-targeted therapies for cancers and other diseases has recently announced the CFDA approval of the IND application for APG-1387. It is a novel small molecule IAP inhibitor under-development for the treatment of the Hepatitis B virus (HBV) infection. It is the first IAP inhibitor to be studied in patients with HBV in China. As China accounts for approximately one-third of HBV carriers globally.